Q-Line Biotech share price
NSE: QLINEHealthcare Equipment & Supplies
Last close ₹529.55down ₹39.45 (6.93%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹569.00.
Range of traded prices from listing on 29 May 2026 to 23 Oct 2026
₹431.00Low, 29 May 2026₹735.00High, 15 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹1,235 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 17 Jun 2026
- 22.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in May 2026
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 17 Jun 2026
- 22.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 17 Jun 2026
- 0.92
- Volume, NSEVolume. Shares traded on the last trading day.
- 1,33,600
Results
Consolidated; ₹ crore, the charts by years to March, the table by half year.Half-yearly results
Half year to Mar 2026, against the half year beforeFiled 17 Jun
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹198 Crup 37.65%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹34 Crup 61.41%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 17.4%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2025Filed 17 Jun | Mar 2026Filed 17 Jun |
|---|---|---|
| Revenue | 144 | 198 |
| Net profit | 21 | 34 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 14.8% | 17.4% |
Consolidated. The 2 half years from Sep 2025, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- Sale of Product ManufacturedSale of Product Manufactured, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹230 Cr67.4%
- Sale of Traded GoodsSale of Traded Goods, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹112 Cr32.6%
Mutual funds holding it
1 fund disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- AddedAdded. Funds that held more shares than at the end of the month before.
- 1
| Fund | |||
|---|---|---|---|
 Abakkus Small Cap FundAbakkus Mutual Fund | 5,13,600 | 1.08% | ₹35.0 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Medical Equipment & Supplies, 27 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Q-Line Biotech in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Poly MedicurePOLYMED | 14,637 | 46.5 | 4.7 | 32.3 | +18.3% | −11.9% | 10.7% | 9.5% | 0.24% |
 Molbio DiagnosticsMOLBIO | 14,279 | – | – | – | – | – | – | – | 0.00% |
 Fischer Medical VenturesFISCHER | 1,738 | 58.1 | – | – | +196.0% | +354.6% | 8.3% | 10.2% | 0.20% |
 Tarsons ProductsTARSONS | 1,596 | 143.9 | 2.5 | 16.4 | +10.6% | −59.7% | 1.8% | 1.5% | 0.00% |
 Laxmi DentalLAXMIDENTL | 937 | 30.3 | 3.8 | 20.2 | – | – | 13.7% | 12.0% | 0.00% |
 Hemant Surgical IndustriesHSIL | 829 | 45.6 | – | – | +117.4% | +126.2% | 18.1% | – | 0.00% |
 Vasa DenticityDENTALKART | 794 | – | 4.6 | – | – | – | – | – | 0.00% |
 Osel DevicesOSELDEVICE | 605 | 20.7 | 3.0 | – | – | – | 14.3% | – | 0.29% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 564.00 | 564.00 | 520.10 | 529.55 | 536.52 | 1,33,600 | – |
| 22 Oct 2026 | 558.00 | 593.00 | 558.00 | 569.00 | 575.72 | 85,200 | 80.3% |
| 21 Oct 2026 | 605.00 | 612.55 | 551.10 | 572.45 | 568.38 | 1,80,800 | 58.6% |
| 19 Oct 2026 | 630.00 | 630.00 | 597.00 | 600.55 | 608.29 | 58,000 | 68.3% |
| 16 Oct 2026 | 595.00 | 637.90 | 573.05 | 628.85 | 604.50 | 1,80,800 | 49.6% |
| 15 Oct 2026 | 613.00 | 618.95 | 595.00 | 598.30 | 606.50 | 48,400 | 68.6% |
| 14 Oct 2026 | 605.05 | 635.95 | 601.00 | 611.65 | 615.98 | 72,000 | 61.1% |
| 13 Oct 2026 | 597.00 | 607.50 | 577.15 | 601.75 | 589.25 | 1,82,000 | 59.1% |
| 12 Oct 2026 | 637.00 | 655.00 | 599.00 | 604.75 | 618.63 | 1,19,600 | 62.9% |
| 9 Oct 2026 | 655.75 | 655.75 | 632.00 | 636.20 | 639.30 | 1,01,600 | 54.7% |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Q-Line Biotech Limited
- NSE symbol
- QLINE
- ISIN
- INE1G2W01011
- Industry
- Healthcare Equipment & Supplies
- Listed
- May 2026
- Face value
- ₹10